BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. World J Gastroenterol 2021; 27(35): 5851-5889 [PMID: 34629806 DOI: 10.3748/wjg.v27.i35.5851] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Surci N, Rösch CS, Kirchweger P, Havranek L, von Boetticher P, Fischer I, Wundsam HV, Biebl M, Függer R. The Rate of Avoidable Pancreatic Resections at a High-Volume Center: An Internal Quality Control and Critical Review. J Clin Med 2023;12. [PMID: 36836160 DOI: 10.3390/jcm12041625] [Reference Citation Analysis]
2 Guo X, Song X, Long X, Liu Y, Xie Y, Xie C, Ji B. New nomogram for predicting lymph node positivity in pancreatic head cancer. Front Oncol 2023;13:1053375. [PMID: 36761960 DOI: 10.3389/fonc.2023.1053375] [Reference Citation Analysis]
3 El-nady MAA, Haridy MA, Hassan AM, Abdelwahid SR, Mohammed MF, Ead KA. Role of endoscopic ultrasound in primary staging and vascular assessment of pancreatic cancer.. [DOI: 10.21203/rs.3.rs-2415814/v1] [Reference Citation Analysis]
4 Menadi S, Cacan E. Promoter hypomethylation upregulates ANXA2 expression in pancreatic cancer and is associated with poor prognosis.. [DOI: 10.21203/rs.3.rs-2306538/v1] [Reference Citation Analysis]
5 Nduma BN, Ambe S, Ekhator C, Fonkem E. Geographical Distribution of Pancreatic Cancer in the State of Mississippi by Incidence and Mortality From 2003 to 2019. Cureus 2022. [DOI: 10.7759/cureus.31605] [Reference Citation Analysis]
6 Gocun PU, Simsek B, Ekinci O, Ekmen N, Arhan M, Karakan T, Ibis M, Cindoruk M. Risk of Malignancy Using the Diagnostic Categories Proposed by the World Health Organization International System for Reporting Pancreaticobiliary Cytopathology. Acta Cytol 2022;66:475-85. [PMID: 35732161 DOI: 10.1159/000525276] [Reference Citation Analysis]
7 Girotti AW, Fahey JF, Korytowski W. Role of nitric oxide in hyper-aggressiveness of tumor cells that survive various anti-cancer therapies. Crit Rev Oncol Hematol 2022;179:103805. [PMID: 36087851 DOI: 10.1016/j.critrevonc.2022.103805] [Reference Citation Analysis]
8 Tong S, Yu Z, Yin F, Yang Q, Chu J, Huang L, Gao W, Qian M. Manganese-based Prussian blue nanoparticles inhibit tumor proliferation and migration via the MAPK pathway in pancreatic cancer. Front Chem 2022;10. [DOI: 10.3389/fchem.2022.1026924] [Reference Citation Analysis]
9 Fan L, Wang X, Chang Q, Wang Y, Yang W, Liu L. IL2RA is a prognostic indicator and correlated with immune characteristics of pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2022;101:e30966. [PMID: 36281157 DOI: 10.1097/MD.0000000000030966] [Reference Citation Analysis]
10 Pedrazzoli S. Surgical treatment of pancreatic cancer: Currently debated topics on morbidity, mortality, and lymphadenectomy. Surgical Oncology 2022. [DOI: 10.1016/j.suronc.2022.101858] [Reference Citation Analysis]
11 Zhang G, Li B, Yin X, Gao S, Shen S, Wang H, Shi X, Liu W, Zheng K, Jing W, Zhang Y, He T, Li G, Hu X, Guo S, Jin G. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases. Int J Surg 2022;104:106786. [PMID: 35868619 DOI: 10.1016/j.ijsu.2022.106786] [Reference Citation Analysis]
12 Zhao H, Liu H, Yang Y, Wang H. The Emerging Role of EVA1A in Different Types of Cancers. Int J Mol Sci 2022;23:6665. [PMID: 35743108 DOI: 10.3390/ijms23126665] [Reference Citation Analysis]
13 Zheng L, Liu H. Prognostic association between NLRP3 inflammasome expression level and operable pancreatic adenocarcinoma. Int J Biol Markers 2022;:3936155221096690. [PMID: 35686324 DOI: 10.1177/03936155221096690] [Reference Citation Analysis]
14 Shi H, Chen Z, Dong S, He R, Du Y, Qin Z, Zhou W. A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02362-2] [Reference Citation Analysis]
15 Ortega MA, Fraile-martinez O, Pekarek L, García-montero C, Alvarez-mon MA, Castellanos AJ, García-honduvilla N, Buján J, Alvarez-mon M, Sáez MA, Guijarro LG, Asúnsolo A. Oxidative Stress Markers Are Associated with a Poor Prognosis in Patients with Pancreatic Cancer. Antioxidants 2022;11:759. [DOI: 10.3390/antiox11040759] [Reference Citation Analysis]
16 Ramya Devi KT, Karthick D, Saravanaraj KS, Jaganathan MK, Ghorai S, Hemdev SP. The roles of microRNA in pancreatic cancer progression. Cancer Invest 2022;:1-26. [PMID: 35333689 DOI: 10.1080/07357907.2022.2057526] [Reference Citation Analysis]
17 Nagata K, Kajiwara M, Fujikawa T. Long-Term Survival of a Patient With Peritoneal Carcinomatosis From Pancreatic Cancer Maintained by Nanoliposomal Irinotecan as Third-Line Chemotherapy. Cureus 2022. [DOI: 10.7759/cureus.22355] [Reference Citation Analysis]
18 Garajova I, Balsano R, Coriano' M, Gelsomino F, Tovoli F, De Lorenzo S, Del Rio P, Dalla Valle R, Ravaioli M, Leonardi F. Should patients on levothyroxine therapy be screened for pancreatic cancer? Acta Biomed 2022;93:e2022268. [PMID: 36533763 DOI: 10.23750/abm.v93i6.13366] [Reference Citation Analysis]